000			02905na a2200241 4500
003			H12O
005			20180417112610.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aNegreira Cepeda, Sagrario _91355 _ePediatría
100			_aRuiz Contreras, Jesús _9811 _ePediatría
245	0	0	_aLaboratory-based, 2-year surveillance of pediatric parapneumonic pneumococcal empyema following heptavalent pneumococcal conjugate vaccine universal vaccination in Madrid. _h[artículo]
260			_bPediatric Infectious Disease Journal, _c2011
300			_a30(6):471-474.
500			_aFormato Vancouver: Picazo J, Ruiz-Contreras J, Casado-Flores J, Negreira S, Del Castillo F, Hernández-Sampelayo T, et al. Laboratory-based, 2-year surveillance of pediatric parapneumonic pneumococcal empyema following heptavalent pneumococcal conjugate vaccine universal vaccination in Madrid. Pediatr Infect Dis J. 2011;30(6):471-4.
501			_aPMID: 21266938
504			_aContiene 27 referencias
520			_aBackground: In October 2006, the heptavalent pneumococcal conjugate vaccine was included in the Madrid vaccination calendar, warranting serotype (St) surveillances in pneumococcal pediatric parapneumonic empyema (PPE). Methods: A prospective 2-year (May 2007-April 2009) laboratory-confirmed PPE surveillance was performed in 22 hospitals. All isolates (for serotyping) and culture-negative pleural fluids were sent to the reference laboratory for polymerase chain reaction (PCR) analysis. Results: We identified 138 PPEs. Pneumococcal etiology was confirmed in 100 cases: 38 by culture, 62 by PCR. Mean age was 44.64 +/- 26.64 months; 51.0% were male. Similar pneumococcal PPE distribution was found by age: 21% to 28% in <24, >= 24-<36, >= 36-< 60, and >= 60 months. PPE-associated Sts were St 1 (38%), St 5 (15%), St 19A (11%), St 7F (9%), St 3 (8%), and others (19%). St 1 was the most common in >36 months, with similar rates to St 19A in <24 months (approximate to 30%). In >= 24-<= 36 months, St 3 (21.7%), St 1 and St 5 (17.4% each) were the most frequent. No differences in demographic data, vaccination status, length of hospitalization, and outcome were found between culture-negative (PCR positive) and culture-positive PPE patients, with significantly higher percentages of St 1 and St 5 in culture-positive PPEs. Total rates of St 1 (38%), St 5 (15%), and St 7F (9%) would have been over-represented considering only positive-culture PPEs (n = 38), by increasing to 52.6% (St 1), 23.7% (St 5), and 10.5% (St 7F). The 13-valent pneumococcal conjugate vaccine would cover 84.0% of Sts causing PPEs. Conclusions: PCR is essential for determining the specific etiology of PPE.
710			_9446 _aServicio de Pediatría-Neonatología
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/5/pc5922.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c5922 _d5922